GSC
AZN icon

G&S Capital’s AstraZeneca AZN Stock Holding History

G&S Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,901
Closed -$1.41M – 98
2020
Q3 		$1.41M Buy
+12,901
New +$1.43M 1.02% 34
2020
Q2 		– Sell
-97
Closed -$8K – 72
2020
Q1 		$8K Hold
97
– – 0.01% 137
2019
Q4 		$9K Hold
97
– – 0.01% 177
2019
Q3 		$9K Hold
97
– – 0.01% 173
2019
Q2 		$8K Hold
97
– – ﹤0.01% 186
2019
Q1 		$8K Buy
+97
New +$7.65K ﹤0.01% 178

Other funds holding AZN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

G&S Capital's AZN Position: Q4 2020 in Review

G&S Capital sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 12,901 shares — an estimated $1.41M sold.

G&S Capital first reported a position in AZN in Q1 2019 and held it in 6 quarters. The position peaked at $1.41M in Q3 2020. 785 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

  • G&S Capital reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
  • G&S Capital sold 12,901 AstraZeneca shares in Q4 2020, an estimated $1.41M.
  • G&S Capital first reported a position in AstraZeneca in Q1 2019 and held it in 6 quarters.
  • G&S Capital's AstraZeneca position peaked at $1.41M in Q3 2020.
  • 785 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on G&S Capital's 13F filing for Q4 2020, filed 21 Jan 2021.